BenzingaAugust 13, 2026 at 7:46 AM NY2 Months Ago
Truist Securities Maintains Hold on Apogee Therapeutics, Raises Price Target to $135
Truist Securities analyst Danielle Brill maintains Apogee Therapeutics (NASDAQ:APGE) with a Hold and raises the price target from $81 to $135.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
